Cargando…
Adaptive crossover designs for assessment of symptomatic treatments targeting behaviour in neurodegenerative disease: a phase 2 clinical trial of intranasal oxytocin for frontotemporal dementia (FOXY)
BACKGROUND: There are currently no treatments for empathy deficits in neuropsychiatric disorders. Acute administration of the hormone oxytocin has been associated with symptomatic improvements across animal models and several neuropsychiatric disorders, but results of the majority of oxytocin random...
Autores principales: | Finger, Elizabeth, Berry, Scott, Cummings, Jeffrey, Coleman, Kristy, Hsiung, Robin, Feldman, Howard H., Boxer, Adam |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6161323/ https://www.ncbi.nlm.nih.gov/pubmed/30261917 http://dx.doi.org/10.1186/s13195-018-0427-2 |
Ejemplares similares
-
Financial capacity in frontotemporal dementia and related presentations
por: Gill, Sascha, et al.
Publicado: (2019) -
Oxytocin in Huntington’s disease and the spectrum of amyotrophic lateral sclerosis-frontotemporal dementia
por: Bergh, Sofia, et al.
Publicado: (2022) -
Foxi2 Is an Animally Localized Maternal mRNA in Xenopus, and an Activator of the Zygotic Ectoderm Activator Foxi1e
por: Cha, Sang-Wook, et al.
Publicado: (2012) -
Anomia is present pre-symptomatically in frontotemporal dementia due to MAPT mutations
por: Bouzigues, Arabella, et al.
Publicado: (2022) -
A Positive Regulatory Loop between foxi3a and foxi3b Is Essential for Specification and Differentiation of Zebrafish Epidermal Ionocytes
por: Hsiao, Chung-Der, et al.
Publicado: (2007)